Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification.

Abstract

We report the case of a 44-year-old female with a prior diagnosis of Sjögren's syndrome who was treated for metastatic anal squamous cell carcinoma with second-line pembrolizumab and has achieved a sustained partial response after a follow-up of 13 months. Comprehensive genomic profiling was remarkable for PD-L1 and PD-L2 amplification and a high tumor mutational burden (19 mutations per megabase). To the best of our knowledge, we present the first report to correlate PD-L1 and PD-L2 amplification with good outcomes of immune checkpoint inhibition in metastatic anal squamous cell carcinoma.

• Authors: Francinne T Tostes, Italo Fernandes, Vanderlei Segatelli, Donato Callegaro, Roberto Carmagnani Pestana
• Journal: Clinical colorectal cancer (Clin Colorectal Cancer) Vol. 20 Issue 4 Pg. 350-353 (12 2021) ISSN: 1938-0674 [Electronic] United States
• PMID: 34154923 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2021. Published by Elsevier Inc.

Chemical References

• Antibodies, Monoclonal, Humanized
• B7-H1 Antigen
• pembrolizumab

Topics

• Adult
• Antibodies, Monoclonal, Humanized
• Anus Neoplasms (drug therapy, genetics)
• B7-H1 Antigen (genetics)
• Carcinoma, Squamous Cell (drug therapy, genetics)
• Female
• Humans